Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain
Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.
Scientists Are Pretty Sure They Found a Portal to the Fifth Dimension
The study seeks to explain the presence of dark matter using a WED model. The scientists studied fermion masses, which they believe could be communicated into the fifth dimension through portals, ...
The Pharma Letter10d
Fermion and Simcere partner to develop novel analgesic
Fermion Technology partners with Simcere Pharmaceutical to develop and commercialise FZ002-037, a clinical-stage non-opioid ...
Pharmabiz11d
Fermion and Simcere Pharma ink partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4
Fermion and Simcere Pharma ink partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4: Guangzhou, China Monday, January 20, 2025, 11:00 Hrs [IST] ...
Hosted on MSN11mon
China NMPA grants IND clearance for Fermion’s TYK2 JH2 inhibitor
The China National Medical Products Administration (NMPA) has granted clearance for the investigational new drug (IND) application of Guangzhou Fermion Technology’s FZ007-119. This is the ...
Morningstar13d
Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain
GUANGZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical ...